**Table S1:** Overview of the RFS rates for all patients and group analyses

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Patient Groups (number of transplants/patients)** | **Relapse-Free Survival (%)** | | | ***P*-value**  **(log-rank test)** |
|  | One-year | Two-year | Three-year |  |
| All transplanted patients (80) | 47.5 | 40.7 | 37.3 |  |
| MUD (49)  MRD (21)  MMUD (10) | 46.9  52.4  40.0 | 38.0  47.1  40.0 | 35.4  39.3  40.0 | 0.76 |
| CR (37)  Non-CR (43) | 48.6  46.5 | 37.5  41.5 | 34.1  38.0 | 0.907 |
| <50 years (27)  ≥50 years (53) | 44.4  49.1 | 37.0  43.1 | 33.3  40.2 | 0.969 |
| AML patients (58) | 43.3 | 38.1 | 33.5 |  |

AML, acute myeloid leukemia; CR, complete remission; MMUD, mismatched unrelated donor; MRD, matched-related donor; MUD, matched-unrelated donor.

**Table S2:** Overview of the OS rates for all patients and group analyses

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Patient Groups (number of transplanted patients)** | **Overall Survival (%)** | | | ***P*-value**  **(log-rank test)** |
|  | One-year | Two-year | Three-year |  |
| All patients (77) | 59.3 | 49.3 | 45.4 |  |
| MUD (48)  MRD (20)  MMUD (9) | 56.8  70.0  48.0 | 49.9  48.1  48.0 | 46.7  40.1  48.0 | 0.95 |
| CR (35)  Non-CR (42) | 65.6  54.3 | 53.3  46.2 | 45.1  46.2 | 0.996 |
| <50 years (25)  ≥50 years (52) | 58.1  60.3 | 54.2  47.4 | 44.4  44.5 | 0.785 |
| AML patients only (58) | 56.5 | 48.9 | 43.5 |  |

AML, acute myeloid leukemia; CR, complete remission; MMUD, mismatched unrelated donor; MRD, matched-related donor; MUD, matched-unrelated donor.